Fate Therapeutics, Inc. F6T.F Stock
Fate Therapeutics, Inc. Price Chart
Fate Therapeutics, Inc. F6T.F Financial and Trading Overview
| Fate Therapeutics, Inc. stock price | 3.33 EUR |
| Previous Close | 5.04 EUR |
| Open | 5.28 EUR |
| Bid | 5.28 EUR x 140000 |
| Ask | 5.34 EUR x 130000 |
| Day's Range | 5.28 - 5.28 EUR |
| 52 Week Range | 3.86 - 35.27 EUR |
| Volume | 76 EUR |
| Avg. Volume | 33 EUR |
| Market Cap | 519.67M EUR |
| Beta (5Y Monthly) | 1.48838 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.79 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 109.83 EUR |
F6T.F Valuation Measures
| Enterprise Value | 202.65M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.9932075 |
| PEG Ratio (5 yr expected) | 2.62 |
| Price/Sales (ttm) | 3.796903 |
| Price/Book (mrq) | 1.0861608 |
| Enterprise Value/Revenue | 1.481 |
| Enterprise Value/EBITDA | -0.819 |
Trading Information
Fate Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.48838 |
| 52-Week Change | -74.026% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 35.27 EUR |
| 52 Week Low | 3.86 EUR |
| 50-Day Moving Average | 5.06 EUR |
| 200-Day Moving Average | 12.21 EUR |
F6T.F Share Statistics
| Avg. Volume (3 month) | 33 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 98.38M |
| Float | 83.7M |
| Short Ratio | N/A |
| % Held by Insiders | 1.50% |
| % Held by Institutions | 106.35% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -171.63% |
| Operating Margin (ttm) | -191.80% |
| Gross Margin | -128.55% |
| EBITDA Margin | -180.70% |
Management Effectiveness
| Return on Assets (ttm) | -22.042% |
| Return on Equity (ttm) | -42.29% |
Income Statement
| Revenue (ttm) | 136.87M EUR |
| Revenue Per Share (ttm) | 1.41 EUR |
| Quarterly Revenue Growth (yoy) | 220.29% |
| Gross Profit (ttm) | -224154000 EUR |
| EBITDA | -247323008 EUR |
| Net Income Avi to Common (ttm) | -234912000 EUR |
| Diluted EPS (ttm) | -2.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 408.9M EUR |
| Total Cash Per Share (mrq) | 4.16 EUR |
| Total Debt (mrq) | 107.62M EUR |
| Total Debt/Equity (mrq) | 22.54 EUR |
| Current Ratio (mrq) | 9.001 |
| Book Value Per Share (mrq) | 4.863 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -212455008 EUR |
| Levered Free Cash Flow (ttm) | -131318376 EUR |
Profile of Fate Therapeutics, Inc.
| Country | Germany |
| State | CA |
| City | San Diego |
| Address | 12278 Scripps Summit Drive |
| ZIP | 92131 |
| Phone | 858 875 1800 |
| Website | https://www.fatetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 551 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Q&A For Fate Therapeutics, Inc. Stock
What is a current F6T.F stock price?
Fate Therapeutics, Inc. F6T.F stock price today per share is 3.33 EUR.
How to purchase Fate Therapeutics, Inc. stock?
You can buy F6T.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fate Therapeutics, Inc.?
The stock symbol or ticker of Fate Therapeutics, Inc. is F6T.F.
Which industry does the Fate Therapeutics, Inc. company belong to?
The Fate Therapeutics, Inc. industry is Biotechnology.
How many shares does Fate Therapeutics, Inc. have in circulation?
The max supply of Fate Therapeutics, Inc. shares is 119.59M.
What is Fate Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Fate Therapeutics, Inc. PE Ratio is now.
What was Fate Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Fate Therapeutics, Inc. EPS is -1.79 EUR over the trailing 12 months.
Which sector does the Fate Therapeutics, Inc. company belong to?
The Fate Therapeutics, Inc. sector is Healthcare.